An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol. 5:e1000581.. 2009.
Modelling the association between patient characteristics and the change over time in a disease measure using observational cohort data. Stat Med. 28:3260-75.. 2009.
Molecular phylodynamics of the heterosexual HIV epidemic in the United Kingdom. PLoS Pathog. 5:e1000590.. 2009.
Phylodynamic analysis of non-B HIV in the United Kingdom reveals substantial post-immigration transmission but longer intervals between transmissions than for subtype B. 16th Conference on Retroviruses and Opportunistic Infections, February 2009.. 2009.
Positive and negative drug selection pressures on the N348I connection domain mutation; new insights from in vivo data. 18th International HIV Drug Resistance Workshop, June 2009.. 2009.
Effect of HIV-1 subtype on virological and immunological response to first-line HAART. 6th European HIV Drug Resistance Workshop, 26-28 March 2008.. 2008.
Effect of HIV-1 subtype on virological and immunological response to first-line HAART. British HIV Association 14th Annual Conference, 23-25 April 2008.. 2008.
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.. 2008.
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.. 2008.
The impact of resistance testing in ARV-naive patients: does it guide optimal therapy selection and improve long-term outcomes? British HIV Association 14th Annual Conference, 23-25 April 2008.. 2008.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.. 2008.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.. 2008.
Long-term probability of detecting HIV drug resistance in drug-naive patients starting currently recommended first-line combination ART. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.. 2008.
Phylogenetic surveillance of viral genetic diversity and the evolving molecular epidemiology of human immunodeficiency virus type 1. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.. 2008.
Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors. Antivir Ther. 13:771-7.. 2008.
Prevalence and patterns of antiretroviral drug resistance at low plasma HIV RNA load levels. 17th International HIV Drug Resistance Workshop, 10-14 June 2008.. 2008.
Recent phylodynamics of the HIV epidemic among MSM in the UK. 15th Conference on Retroviruses and Opportunistic Infections, February 2008.. 2008.
Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.. 2008.
What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? J Antimicrob Chemother. 61:705-13.. 2008.